State generic substitution laws

On Sept. 1, 2019, pharmacists in 19 states were required by law to substitute an equivalent generic when filling a prescription written for a brand-name drug. In the other 31 states and Washington, DC, substitution was permitted but left to the pharmacist. Those counts come from a 2021 analysis in JAMA Internal Medicine¹ that coded every state's drug product selection law as it stood on that date.

That study also found that seven states and DC required the patient's consent before a generic could be dispensed, and that 31 states and DC required the patient to be told about the swap separately from what was printed on the package.

These rules sit underneath almost every prescription filled in the US, yet they are invisible to most patients. They decide whether a generic appears automatically, whether a pharmacist has to ask first, and what a prescriber has to write to stop it. A federal reference book, the Orange Book, ended up as the backbone of 51 separate legal systems.

Why FDA publishes a list for the states

FDA approves generics, and sets what a generic must share with its brand (our piece on what can differ covers the rest). It does not decide whether a pharmacist may hand one out in place of a brand; states do. The Orange Book preface³ explains how that split came about. To contain drug costs, it says, “virtually every state has adopted laws and/or regulations that encourage the substitution of drug products.” Some states limited substitution to drugs on an approved list (a positive formulary). Others allowed it for everything except drugs on a prohibited list (a negative formulary).

By the late 1970s so many states were asking FDA for help building those lists that the agency decided one national list would work better. On May 31, 1978, the FDA commissioner wrote to every state announcing it. A proposed version circulated in January 1979, and the first edition appeared in October 1980³, alongside a final rule on therapeutic equivalence.

FDA still frames the book as advice. Its preface³ says the therapeutic equivalence evaluations “are not official FDA actions affecting the legal status of products.” It also says products rated equivalent “can be substituted with the full expectation that the substituted product can be expected to have the same clinical effect and safety profile as the prescribed product.” States write that judgment into law by tying substitution to FDA's two-letter codes, explained in our guide to therapeutic equivalence codes. In the Orange Book data files⁴ FDA posted in October 2026, 21,924 of 24,790 prescription product listings carried an A-series code, meaning FDA considers them therapeutically equivalent to at least one other listed product, usually on the strength of the bioequivalence studies behind each generic.

Four ways state laws differ

Researchers on the JAMA Internal Medicine team¹ scored each jurisdiction on four features that make substitution harder or easier. Higher scores meant more requirements limiting substitution. Nine states and DC scored 3 or more on the 0-to-4 scale.

Permissive states are simply the remainder of the 51 jurisdictions after the 19 mandatory states. Rules for biologics were tighter almost everywhere. The study found¹ that 45 states had more stringent requirements for substituting an interchangeable biologic than for a generic, most often a requirement to notify the prescriber. Our explainer on biosimilars and generics covers why the two pathways differ.

What consent rules do to generic use

Consent requirements sound protective, and the research suggests they carry a cost. A 2010 Health Affairs study² used national Medicaid data to compare use of generic simvastatin across states after the brand's patent expired. FDA records on openFDA⁹ show the first generic simvastatin approvals on June 23, 2006. States that required patient consent before substitution saw rates of generic substitution 25 percent lower than states without that requirement.

Its authors estimated² that state Medicaid programs could save more than $100 million on three top-selling drugs then nearing patent expiration by dropping consent requirements. They wrote that consent rules are “probably intended to increase patient autonomy” but that policy makers “should consider the sizable opportunity costs.” For old generics the gap per prescription is now small. In GxRadar's analysis of CMS NADAC data¹⁰, pharmacies paid an average of about 3.2 cents per simvastatin 20 mg tablet in October 2026, or roughly 97 cents for 30 tablets. The dollar stakes are larger when a high-priced brand first faces generic competition. See our page on Medicaid and generic drug prices for how state programs pay for those fills.

One state's statute, line by line

North Carolina's law shows how the pieces fit together in practice. Under G.S. 90-85.28⁵, a pharmacist filling a brand-name prescription “may select” an equivalent drug, which makes the state permissive. The selected product must meet listed standards, among them manufacture under current good manufacturing practice and adequate provisions for recall. The pharmacist may not substitute unless the product's price to the purchaser is lower than the prescribed drug's.

A prescriber blocks substitution by signing a “Dispense as Written” line on a two-line prescription form, by handwriting the phrase, or by saying so on a phone order. The statute also carries the state's rules for interchangeable biologics. Within five business days of dispensing one, the pharmacist must tell the prescriber which product and manufacturer were dispensed, through an electronic record the prescriber can access or, failing that, by fax, phone or similar means.

North Carolina also has a narrower rule for a short list of drugs, added by a 1997 session law⁷. Under subsection (b1), a prescription for a “narrow therapeutic index drug” must be refilled with the same manufacturer's product last dispensed, unless the pharmacist notifies the prescriber first and both prescriber and patient give documented consent to the change. G.S. 90-85.27⁶ defines these as drugs with less than a twofold difference between the minimum toxic and minimum effective blood concentrations, or with erratic absorption that requires blood-level monitoring. The list the state Board of Pharmacy published in January 2003⁸ included levothyroxine tablets, warfarin tablets, carbamazepine, digoxin, lithium and phenytoin. A companion piece, the pharmacist’s role in generic substitution, looks at how those rules play out at the counter.

What to watch

The JAMA snapshot describes the law as of 2019, and legislatures have kept amending these statutes since. North Carolina's statute alone was amended in 2015, 2022 and 2025, according to the history note on the current text⁵. Anyone tracking a particular state can start with the state pharmacy practice act and board of pharmacy rules, and with our pharmacist script for questions about what a given pharmacy is allowed to do.